TrialInternational journal of clinical oncology2022

Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).

Hiroshi Matsuoka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.